1. Home
  2. PRO vs PHAT Comparison

PRO vs PHAT Comparison

Compare PRO & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROS Holdings Inc.

PRO

PROS Holdings Inc.

HOLD

Current Price

$23.25

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$14.70

Market Cap

942.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRO
PHAT
Founded
1985
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
942.6M
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
PRO
PHAT
Price
$23.25
$14.70
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$24.54
$17.33
AVG Volume (30 Days)
1.2M
799.8K
Earning Date
10-27-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$351,682,000.00
$147,190,000.00
Revenue This Year
$10.50
$218.59
Revenue Next Year
$10.86
$84.38
P/E Ratio
N/A
N/A
Revenue Growth
8.92
460.30
52 Week Low
$13.61
$2.21
52 Week High
$29.84
$16.27

Technical Indicators

Market Signals
Indicator
PRO
PHAT
Relative Strength Index (RSI) 76.65 54.15
Support Level $23.06 $14.12
Resistance Level $23.20 $16.27
Average True Range (ATR) 0.05 0.67
MACD -0.04 -0.11
Stochastic Oscillator 95.24 28.67

Price Performance

Historical Comparison
PRO
PHAT

About PRO PROS Holdings Inc.

Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: